Wangyang You
Henan Provincial Center for Disease Control and Prevention(CN)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Vaccine Coverage and Hesitancy, Respiratory viral infections research, Pneumonia and Respiratory Infections
Most-Cited Works
- → Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial(2020)1,207 cited
- → Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults(2021)828 cited
- → Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes(2020)803 cited
- → Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial(2021)198 cited
- → Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial(2021)40 cited
- → Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial(2022)21 cited
- → Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study(2023)7 cited
- → Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18–49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study(2024)7 cited
- → Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months(2023)7 cited
- → Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects ≥3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial(2022)6 cited